Biora Therapeutics (NASDAQ:BIOR) Shares Down 3.5%

Biora Therapeutics, Inc. (NASDAQ:BIOR) fell 3.5% on Tuesday . The company traded as low as $0.68 and last traded at $0.70. 509,538 shares changed hands during trading, an increase of 10% from the average session volume of 464,427 shares. The stock had previously closed at $0.73.

Wall Street Analysts Forecast Growth

Separately, HC Wainwright restated a “buy” rating on shares of Biora Therapeutics in a research report on Tuesday, January 2nd.

Biora Therapeutics Stock Down 3.5 %

The stock has a market cap of $21.22 million, a P/E ratio of -0.08 and a beta of 1.09. The company’s 50 day moving average price is $1.01 and its 200-day moving average price is $1.35.

Institutional Inflows and Outflows

Several large investors have recently bought and sold shares of BIOR. Vanguard Group Inc. grew its position in shares of Biora Therapeutics by 82.2% in the 4th quarter. Vanguard Group Inc. now owns 507,935 shares of the company’s stock valued at $686,000 after buying an additional 229,183 shares during the last quarter. Virtu Financial LLC acquired a new position in shares of Biora Therapeutics in the fourth quarter worth approximately $27,000. State Street Corp boosted its holdings in Biora Therapeutics by 88.2% in the second quarter. State Street Corp now owns 33,073 shares of the company’s stock valued at $127,000 after acquiring an additional 15,500 shares during the last quarter. Geode Capital Management LLC increased its position in Biora Therapeutics by 83.3% during the 2nd quarter. Geode Capital Management LLC now owns 80,812 shares of the company’s stock valued at $311,000 after purchasing an additional 36,720 shares during the period. Finally, Schonfeld Strategic Advisors LLC bought a new position in Biora Therapeutics during the 1st quarter worth approximately $118,000. 43.74% of the stock is owned by institutional investors.

About Biora Therapeutics

Biora Therapeutics, Inc, a biotechnology company, engages in developing oral biotherapeutics. The company's targeted therapeutics program uses an ingestible smart capsule for targeted delivery of therapeutics in the gastrointestinal (GI) tract to enhance the treatment of inflammatory bowel diseases; and Systemic oral delivery platform for oral delivery of large molecules for management of chronic diseases.